Technology Bundle ID
TAB-3676

Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy

Applications
Therapeutics
Linked ID
E-036-2013-0
Lead Inventors
Maribeth Eiden (NIMH)
Co-Inventors
Wenqin Xu (NIMH)
ICs
NIMH
This invention relates to a novel gammaretroviral vector packaging cell line and a method of producing gammaretroviral vectors suitable for gene therapy. The described vectors may contain the gibbon ape leukemia virus (GALV) envelope with a CD11D8 epitope tag enabling their purification on a monoclonal antibody conjugated column. These vectors have several advantages over existing systems, including a broader host range, higher infectivity, and lower potential for replication. Further, purification of retroviral vector particles via an epitope tag may remove cellular components and debris toxic to target cells and tissues, providing a safer method of delivery for patients receiving gene therapy.
Commercial Applications
Retroviral vector particles for gene therapy
Competitive Advantages
  • Broader host range
  • Higher infectivity
  • Lower potential for replication
  • Decreased toxicity after purification

Request More Info

Licensing Contact: